# Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia

> **NCT03254173** · PHASE2,PHASE3 · COMPLETED · sponsor: **Catherine Naseef Hunter** · enrollment: 120 (actual)

## Conditions studied

- Advanced Cancer
- Cancer Associated Anorexia - Cachexia

## Interventions

- **DRUG:** Mirtazapine 30 mg oral tablets
- **DRUG:** Placebo oral tablets

## Key facts

- **NCT ID:** NCT03254173
- **Lead sponsor:** Catherine Naseef Hunter
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2019-10-17
- **Final completion:** 2019-10-17
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254173, "Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03254173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*